Skip to content

Postplacental LNG-IUD Ultrasound Use Study

Postplacental LNG-IUD Ultrasound Use Study

Status
Terminated
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04474548
Acronym
PLUS
Enrollment
103
Registered
2020-07-17
Start date
2020-10-05
Completion date
2023-10-01
Last updated
2026-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IUD Insertion Complication

Keywords

IUD, Postpartum, Ultrasound

Brief summary

This study will enroll women planning to have an intrauterine device (IUD) placed for contraception immediately following a vaginal delivery. Women will be randomized to have this procedure done with or without ultrasound guidance. We intend to determine if the routine use of ultrasound to confirm device position reduces the rates of IUD expulsion.

Detailed description

Participants will be screened and consented for participation in the study when they are admitted to Labor and Delivery for delivery and express desire for a post-placental LNG-IUD. If the patient consents for study participation and meets eligibility criteria above, she will be enrolled in the study after achieving vaginal delivery when she is randomized to either IUD insertion with ultrasound or without ultrasound use. See protocol for detailed description of IUD placement and ultrasound use. After placement of IUD with or without ultrasound guidance, patients will be scheduled for a routine postpartum follow-up visit 6-10 weeks after delivery. At the postpartum follow-up visit, providers will assess for IUD expulsion with usual clinical practice, including history, pelvic exam, and additional imaging if IUD strings are not visualized on exam. Several attempts to contact participants who do not attend their postpartum visits will be made to attempt to reschedule appointments and conduct a phone questionnaire assessing for IUD expulsion.

Interventions

OTHERUltrasound use

Ultrasound will be used to determine location of IUD after insertion.

Sponsors

Thomas Jefferson University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
Yes

Inclusion criteria

* Patients admitted to Thomas Jefferson University Labor and Delivery who desire and consent to post-placental LNG-IUD placement * English- and Spanish- speaking patients

Exclusion criteria

* Patients undergoing planned or unplanned Cesarean delivery * Patients who have an allergy or other contraindication to use of LNG-IUD * Patients who tested positive for gonorrhea or chlamydia during pregnancy without treatment and a subsequent negative test of cure * Patients with one or more leiomyomata greater than 3 cm in diameter impinging the uterine cavity * Clinical diagnosis of chorioamnionitis or presumed chorioamnionitis in labor * Postpartum hemorrhage as defined by need for transfusion, estimated blood loss greater than 1000mL, or use of 3 or more doses of uterotonic medications

Design outcomes

Primary

MeasureTime frameDescription
IUD expulsion6-10 weeksThe primary objective is to determine whether the expulsion rate of the LNG-releasing IUD within a 6-10 week period would be different when inserted with ultrasound guidance or with no ultrasound confirmation

Secondary

MeasureTime frameDescription
IUD insertion complication6-10 weeksTo determine if rate of complication with insertion, such as uterine perforation rates, infection rates, or bleeding rates, are different with or without ultrasound guidance
Receiving IUD6-10 weeksTo determine what percentage of patients who desire a post-placental IUD after delivery are able to receive one and to determine if enrolled patients that cannot get an immediate post-placental IUD get an IUD within 6-10 weeks after delivery

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORLisa Perriera, MD, MPH

Thomas Jefferson University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 9, 2026